An open-label comparative bioavailability ( randomized crossover ) study compared a novel twice-daily minitab sprinkle formulation ( @ mg/@ mg , Cipla Pharmaceuticals ) versus innovator syrup in HIV-infected Ugandan infants aged @ to < @ months ( cohort A ) and children aged @-@ years ( cohort B ) and versus Cipla tablets ( @/@ mg ) in children aged @ to < @ years ( cohort C ) .